About Us
diaDexus is a privately held biotechnology company based in South San Francisco, CA, focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value.
For more information, please visit www.diadexus.com.
The PLAC® Test
In July 2003, diaDexus received FDA clearance to market the PLAC Test as an aid in the prediction of coronary heart disease (CHD) risk. In June 2005, the FDA cleared the PLAC Test as the first blood test for determining the risk for ischemic stroke associated with atherosclerosis. The PLAC Test determines levels of Lp-PLA2 (lipoprotein-associated phospholipase A2) in the blood; individuals with elevated levels of Lp-PLA2 have been shown to have an increased risk of ischemic stroke and coronary heart disease.